A Phase 2a, Open-label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Exploratory Treatment Effect of GBT440 in Pediatric Participants With Sickle Cell Disease

Trial Profile

A Phase 2a, Open-label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Exploratory Treatment Effect of GBT440 in Pediatric Participants With Sickle Cell Disease

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs GBT 440 (Primary)
  • Indications Sickle cell anaemia
  • Focus Pharmacokinetics; Therapeutic Use
  • Acronyms HOPE-KIDS 1
  • Sponsors Global Blood Therapeutics
  • Most Recent Events

    • 07 Aug 2017 According to a Global Blood Therapeutics media release, dosing of Cohort 2 has been completed the third-quarter of 2017.
    • 10 Jul 2017 According to a Global Blood Therapeutics media release, first patient in Cohort 2 of this study, age 6 to 11, is dosed and the data from this, cohort 2 is anticipate later in 2017.
    • 10 Jul 2017 According to a Global Blood Therapeutics media release, Cohort 2, portion of this study is recently initiated and will enroll patients age 6 to 11.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top